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Abstract
THE RATE OF PLACENTA ACCRETA AND PREVIOUS EXPOSURE TO UTERINE
SURGERY
Anne Cooper MA, Lisbet Lundsberg PhD, Daniel Bercik, Jessica L. Illuzzi MD. Department of
Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven,
CT.
Placenta accreta is a disorder of abnormal placentation that causes significant maternal morbidity and
mortality, and whose incidence is rising in the US. Accreta is thought to be linked closely to endometrial
disruption introduced by exposure to uterine surgery; its connection to cesarean delivery is wellestablished, however, there is a poorer understanding of the contribution made by other forms of uterine
surgery, and by relatively subjective indications for which women with placenta accreta may have initially
received a cesarean delivery. The aims of the study were to quantify the rate of placenta accreta at YNHH,
the rate of exposure to various uterine surgeries prior to the accreta pregnancy, and the rate of subjective
indication for primary cesarean delivery amongst all patients with placenta accreta from 1995-2011.
Among the 72,845 births during the study period, 249 cases of placenta accreta were identified via query of
pathology records, including 122 focal accreta, 63 accreta vera, 23 increta and 14 percreta.
Twenty-seven cases were excluded due to lost chart, multiple accreta in a single patient, and absence of
baseline birth data for Jan 1995 - June 1996; a total of 100 cases of non-focal accreta were included in the
final analysis. Non-focal accreta is increasing over the study period; the rate was 1.4 cases per 1,000 births;
it increased on average 12% per 3-year period over the course of the study (95% CI -1.6% to 28.5%).
Among all births, women with placenta accreta and a prior index cesarean delivery increased significantly
over the study period, with a mean increase of 21.9% per 3-year period (95% CI1.4% to 46.6%), while
those with placenta accreta and other index uterine surgery increased by 71.1% per 3-year period (95% CI
10.4% to 165%). Over this 15 year period, the cumulative increase in risk of having placenta accreta in the
setting of prior cesarean delivery was 2.69 (95% CI 1.07 – 6.8) while the cumulative increase in risk for
having placenta accreta in the setting of prior other uterine surgery was 14.66 (95% CI 1.64 – 131). There
was no significant difference in rate of placenta accreta with prior index cesarean delivery for subjective or
objective indication. Placenta accreta in the setting of prior uterine surgery is increasing over time. Larger
studies are needed to further elucidate the increasing role of prior uterine surgery on the development of
placenta accreta in the population.
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Introduction
Overview
Placenta accreta is a disorder of abnormal placentation that causes significant maternal
morbidity and mortality, and whose incidence is rising in the US.(1,2,3,4) In placenta
accreta, placental villi invade beyond their usual implantation in the decidua basalis into
or through the myometrium. This impairs a major physiologic mechanism to control
postpartum bleeding, leading to high rates of hemorrhage and increased maternal and
perinatal morbidity and mortality. Women with placenta accreta face a range of
complications, including acute respiratory distress syndrome, disseminated coagulation,
transfusion-related complications, injury to ureters, bladder or bowel, emergency
hysterectomy and death.(1) In the setting of severe hemorrhage, hysterectomy may be
necessary as a lifesaving intervention; despite aggressive surgical intervention, maternal
death rates in placenta accreta have been reported as high as 7%.(5)
The incidence of placenta accreta has risen significantly compared with rates in the
1950s,(6) recent estimates place it at 1 per 533 deliveries to 1 per 2510 deliveries.(6,7)
Cesarean delivery has been identified as a significant factor leading to the increase in
accreta rates, attributed to uterine wall disruption and resulting uterine scar.(6,7,8,9,10)
Other types of uterine instrumentation that disrupt the endometrium are also viewed as
potential contributors, though their role is less clearly defined(1,10,11,12) As patterns of
cesarean delivery and other uterine surgery change, it is important to examine their
potential contribution to the rate of placenta accreta.(3) In the United States, the cesarean
delivery rate increased to 32.9% in 2009, compared with 5% in 1970 and 25% in
1989.(10)
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As rates of cesarean delivery increase, a recent study at one tertiary care center showed
that the majority of indications for primary cesarean from 2003-2009 were done for
indications that can be considered subject to varied interpretation by different clinicians.
These more subjective indications include non-reassuring fetal heart tracing, labor arrest
disorders and suspected macrosomia.(13) Elective cesarean per maternal request can also
be considered subjective, or without objective medical indication. Over time, the use of
other uterine procedures, including myomectomy, has also shifted. To date, there has not
been an effort to examine the rate of exposure to previous uterine surgery among patients
with placenta accreta, in order to better understand the indications that may underlie the
increasing rates of placenta accreta.

Incidence
Rates of placenta accreta are estimated to have increased significantly compared with
rates in the 1950s.(6) Recent estimates place the incidence at 1 per 533 deliveries to 1
per 2510 deliveries,(6,7,14) in comparison with rates from the 1930s-1950s of 1:30,000
births.(15) Estimates of the incidence of placenta accreta vary widely, due to variations
in diagnostic criteria and study population; nevertheless, there is consistent demonstration
in the literature that the rate has increased substantially over time.

Pathogenesis
The placenta is a remarkable organ, constantly undergoing change throughout its
relatively brief existence. Upon implantation of an embryo, the endometrium becomes
known as the decidua, and forms the maternal portion of the placenta. The decidua
develops into several layers: the decidua compactus is the most superficial to the uterine
cavity. Beneath it is the stratum spongiosum, below this is the stratum compactum or
dedicua basalis.(16,17) This barrier layer interacts with invading trophoblastic cells, and
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lies adjacent to the underlying myometrium, with an intervening fibrinoid layer known as
Nitabuch’s layer.(18) At parturition, the decidua sloughs off at the decidua basalis, and
the maternal spiral arteries that penetrate the decidua at right angles to fill the intervillous
space are compressed by uterine contraction and spasm to achieve hemostasis.
Placenta accreta is a relative newcomer to obstetric pathology. It was first documented in
1937 by Irving & Hertig, who described it as “the abnormal adherence, either in whole or
in part, of the afterbirth to the underlying uterine wall,” which they attributed to a
deficiency or absence of the decidua basalis.(19) There are three types of placenta
accreta: placenta accreta vera (more often termed just placenta accreta) denotes
placental attachment directly onto the myometrium without intervening decidua basalis,
increta indicates invasion into the myometrium, percreta denotes penetration through the
myometrium into or beyond the serosa, which may include involvement of nearby
organs, including bladder or bowel.(Fig. 1) The term placenta accreta can be used as an
overarching term that includes all degrees of pathological placental invasion.
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Fig. 1. Types of placenta accreta by degree of invasion.
Placenta accreta can also be categorized according to the surface area of the placenta that
is abnormally adherent, as focal, partial or total.(16) The designation of focal accreta is
useful to denote a small area of abnormal placentation, as small as one cotyledon.(20,21),
however the clinical significance of this finding is less clear.
The key pathologic finding associated with placenta accreta is the absence or deficiency
of the decidual plate, with the finding of placental villi embedded directly onto
myometrium, often described in histopathology as the presence of basal plate myometrial
fibers.(16) More recently, accreta has also been found to include abnormally invasive
extravillous trophoblast, underlining the importance of the balance between decidua and
trophoblastic invasion.(22) Uterine surgery or procedures that disrupt the endometrium
are assumed to increase risk of accreta through their potential disruption of
decidualization, and possible creation of scar tissue.(21) There are several, likely
overlapping, theories advanced to explain the etiology of placenta accreta. The first
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theory is that a deficiency or absence of decidua prevents its usual role in preventing
excessive trophoblast invasion into the myometrium.(23,24) There is also evidence that
deficient vascularization and resulting negative oxygen tension in scarred areas of the
uterus leads trophoblastic cells to invade more deeply to establish adequate blood
supply.(5) Finally, the oldest theory posits that trophoblastic tissue itself is abnormally
invasive.(16,26)

The fact that placenta accreta was first recognized less than 100 years

ago suggests a significant iatrogenic component.(27)

Risk Factors
Although the etiology of placenta accreta is still a topic of debate, the risk factors for
placenta accreta are better understood. According to one study, approximately 95% of
women diagnosed with placenta accreta have identifiable risk factors.(10) The most
common presentation of placenta accreta is a woman with one or more previous cesarean
deliveries and current placenta previa. There is robust evidence that the risk of placenta
accreta also increases significantly with repeated cesarean deliveries.(29,31,32,33) A
prospective observational cohort study of 30,132 women with cesarean delivery without
labor taking place in four academic centers between 1999-2002 scrutinized number of
placenta accreta by number of previous cesarean deliveries. The study identified cases of
accreta via histopathology, or via clinical diagnosis in cases where hysterectomy was not
performed. Specific criteria for clinical diagnosis were not enumerated. They found that
risk of accreta in women with placenta previa rises from 3% in the setting of one
previous cesarean delivery, to 11%, 40%, 61% and 67% with two, three, four and five or
more previous cesarean deliveries, respectively, a trend that is mirrored at a lower rate in
patients without placenta previa, as well.(8) Compared with a first vaginal birth, women
with a first birth by cesarean have 1.9 times higher odds (CI 1.3-2.8) of placenta accreta
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in the subsequent pregnancy.(12) Having two or more cesarean deliveries is associated
with an odds ratio of 8.6 (95% CI 3.54-21.08) for development of placenta accreta in the
subsequent pregnancy.(7) In view of the strength of this association, the increasing rate
of cesarean delivery is agreed to be one of the most significant factors contributing to
placenta accreta.(8,9,11)
Placenta previa is also independently associated with placenta accreta, particularly when
the placenta is overlying a previous uterine scar. Abnormal placentation is often found in
association with placenta previa. Accreta is now seen in 9.3% of women with placenta
previa.(7) Other risk factors include advanced maternal age, multiparity, Asherman
syndrome, leiomyomata, radiation exposure, uterine anomalies, hypertension and
smoking.(1,6,7,11,29,30)
Given their disruption of the endometrium, it is likely that other forms of uterine surgery,
such as myomectomy, endometrial ablation, septum resection, and lysis of adhesions also
contribute to risk of placenta accreta; however, comparably little has been done to
investigate this association, aside from case reports.(34,35) Fibroids contribute to
infertility, and prevalence in the United States may be as high as 13% however, no direct
causal relationship between fibroids and infertility has been established.(36) Treatment is
tailored to the reproductive wishes of the patient, and treatment regimens are shifting
over time, including an effort to study medical therapies; however, myomectomy,
endometrial ablation and other surgical interventions are also still frequently used,(37)
with ongoing debate as to the effectiveness of abdominal versus laparoscopic or robotic
approaches for myomectomy.(38) There is relatively little data available as to rate of
myomectomy over time or outcomes of subsequent pregnancies.(39)
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Diagnosis
Diagnostic imaging

There are three modes of diagnosis for placenta accreta: pre-natal imaging, intrapartum
clinical findings, and histopathology from a placental or uterine specimen. A fourth
mode of diagnosis is in development: immunohistochemical markers that could help
predict presence and/or severity of placenta accreta. (1,21)
Prenatal diagnosis of placenta accreta mainly takes place via ultrasound, usually during
the second or third trimester. Criteria for sonographic diagnosis of placenta accreta
include a range of associated findings, including loss of the normal hypoechoic
retroplacental zone; presence of multiple vascular lacunae within the placenta; blood
vessels or placenta bridging the uterine-placental margin, myometrial-bladder interface or
crossing the uterine serosa; retroplacental myometrial thickness of <1mm; and presence
of numerous coherent vessels visualized with 3-dimensional power Doppler in basal
view.(1) Across four studies, sonographic diagnosis of placenta accreta has been
associated with a sensitivity of 77.0 – 93.0% and specificity of 71.0 – 96.8%, with a PPV
of 65.0 – 87.5% and NPV of 92.0 – 98.0%.(40,41,42,43) Ultrasound is particularly
useful for ruling out accreta, given its high negative predictive value.(40) In women with
low-lying placenta or placenta previa in setting of previous uterine instrumentation, it is
particularly important to be vigilant in screening for placenta accreta.
MRI can also be used in evaluation of placenta accreta, though evidence on its utility is
mixed. It may be particularly useful in cases of posterior placenta(44) or where patient
habitus limits sonography and also has the advantage that it is not operator dependent.
An analysis in 2007 showed that three MRI findings were associated with abnormal
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placentation: abnormal uterine bulging, heterogenous signal intensity, and presence of
dark intraplacental bands on T2-weighted images.(45) One study evaluated ultrasound
and MRI diagnosis of placenta accreta in a cohort of 453 women with placenta previa,
previous cesarean delivery and low-lying anterior placenta, or previous myomectomy; it
found ultrasound to accurately predict placenta accreta in 30 of 39 women and
appropriately rule out accreta in 398 of 414 women (sensitivity 77%, specificity
96%).(42) In the same study, among 42 cases with inconclusive or suspicious findings
on ultrasound, MRI was a useful adjunct: it accurately predicted placenta accreta in 23 of
26 cases, and correctly ruled out placenta accreta in 14 cases (sensitivity 88%, specificity
100%).(42) Given its increased expense and comparable sensitivity and specificity to
ultrasound, MRI is perhaps most often useful as a second stage of evaluation in cases
where ultrasound findings are inconclusive.
The extent of myometrial invasion noted on ultrasound reflects the type of accreta,
particularly denoted by presence of blood vessels or placenta traversing the myometrium
or crossing the serosa. Lower degrees of invasion are more difficult to appreciate, and
there is no data on diagnosis of focal accreta via ultrasound or MRI, though positive
identification would likely be limited to cases with invasion that disrupts macroscopic
architecture.
Clinical Diagnosis

The second mode of diagnosis is intrapartum clinical diagnosis, based on presence of
hemorrhage or retained placenta without a clear plane of separation. In cases of clinical
suspicion, submission of the placenta for pathologic evaluation is warranted. A 2006
study by Silver and colleagues, which established accreta risk relative to number of
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previous cesarean, used both pathologic diagnosis in cases where hysterectomy was
performed, and clinical findings of adherent placenta with difficult removal, in cases
where hysterectomy was not performed.(8) The authors recognize that a possible
limitation of the study was the use of a clinical definition for accreta; however, for their
study, histologic diagnosis was only available when hysterectomy was performed. An
alternative reason for inclusion of clinical diagnostic criteria is among populations where
access to sonography is limited.(32)
Several other studies have used a mix of clinical and pathologic criteria. For instance,
Gielchinsky et al 2002 used the definition below, which was subsequently replicated in
another study: (28)
(1) Difficult manual, piecemeal removal of the placenta, that was
performed if no evidence of placental separation was noticed at least 20
min after parturition, and despite of active management of the third stage
of labour (i.e. administration of intravenous oxytocin, transabdominal
manual massage of the uterus, drainage of blood from the placenta, and
firm-controlled traction of the umbilical cord); OR
(2) sonographic evidence of retained placental fragments requiring
curettage after vaginal delivery; OR
(3) heavy bleeding from implantation site after removing the placenta
during conservatively managed caesarean section, with excision of part of
the uterine wall and the attached placenta, or over-sewing the bleeding
defects; OR
(4) histologic confirmation of a hysterectomy specimen.(29)

Histopathological Diagnosis

The third mode of diagnosis is via histopathology, which relies on demonstrating the
presence of basal plate myometrial fibers, or direct apposition of trophoblastic tissue onto
the underlying myometrium, without intervening decidual tissue.(16) The diagnosis can
be made on hysterectomy specimen, but also on placenta or placenta with uterine biopsy,
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if myometrial fibers are found to be present either immediately adjacent to placental villi
or with only an intervening fibrin layer.(18,20)
Comparison of modes of diagnosis

There are pros and cons of the three diagnostic modalities for accreta: they have different
functions and operate at different times during the pregnancy and peripartum periods.
Their varying use in previous research makes comparison across studies difficult.
Prenatal diagnosis via ultrasound usually occurs during the second and third trimesters,
though it has been documented in the first trimester. Antenatal diagnosis provides the
opportunity for delivery planning, which is an important way to reduce intrapartum
hemorrhage and improve outcomes. Intrapartum clinical diagnosis is made within the
acute management setting, where the diagnosis of accreta is secondary to effective
assessment of the evolving problem and adept management. Clinical severity is also the
major factor used in evaluating the impact of placenta accreta, and can be important in
distinguishing between symptomatic non-focal accreta and asymptomatic cases of focal
accreta. (20,21)
Finally, postpartum pathologic diagnosis occurs on either placental or hysterectomy
specimen and provides the most objective basis for diagnosis; however, it is also subject
to uncertainty, particularly in relation to focal placenta accreta. Focal placenta accreta is
often less clinically severe, and may even be clinically silent, making its relevance
unclear. In contrast, some argue that any case of retained placenta or manual removal of
placenta represents a minor case of abnormally adherent placenta.(16,21,47) One study
compared placentas with basal plate myometrial fibers on histopathology but no clinical
findings of accreta (so-called ‘occult placenta accreta’) with placentas from similar
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deliveries without basal plate myometrial fibers.(48) They found that the occult placenta
accreta cases had a significantly higher level of extravillous trophoblast, signaling that
although they were not symptomatic, they had evidence of the same pathology
underlying overt placenta accreta.(25) Thus, on one hand some argue that focal placenta
accreta is not relevant because it often does not have clinical findings of placenta accreta;
alternatively, if there is a shared pathology, it may help advance our understanding of
accreta.
Variation in diagnostic criteria across accreta research studies

One of the reasons for varying estimates of incidence of placenta accreta is that studies
have used differing diagnostic criteria over time, with a contrast between those that rely
strictly on histopathologic diagnosis, usually from hysterectomy specimen, and those that
accept both clinical and pathologic evidence.
The degree of overlap between clinical suspicion and pathologic diagnosis can be
problematic. In one retrospective review of cases of accreta between 1985 and 1994,
clinical suspicion of placenta accreta was found to correctly identify only 48% of cases.
The remaining 62 of 127 hysterectomy cases with operative diagnosis of accreta were
found on pathology to not meet criteria for placenta accreta.(6) One solution to this has
been to rely on only on pathological diagnosis rather than using clinical criteria; in many
cases, only hysterectomy specimens have been examined, although placenta accreta can
be diagnosed on placental specimens, as well.(49)
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Outcomes of Placenta Accreta
Developing an accurate understanding of the prevalence, risk factors, and options for
prevention and management of placenta accreta is of the utmost importance, given its
particular impact on maternal health.
Women with placenta accreta face a range of sequelae, including not only hemorrhage,
but also blood transfusion with associated complications, injury to local organs, amniotic
fluid embolism, postoperative infection, thromboembolism, multi-organ failure and
death.(1) One case series of 76 patients with accreta found that blood transfusion was
required in 80% of deliveries, and that 40% of cases required transfusion of 4 units or
more of packed red blood cells.(10) Average blood loss at time of delivery can be 30005000mL, and may exceed 10L.(50,51)
In the setting of severe hemorrhage, hysterectomy may be necessary to prevent maternal
death. Placenta accreta is now the leading cause of peripartum hysterectomy in the
developed world.(2,52) One retrospective cohort study of all deliveries occurring in three
hospitals in Dublin, Ireland from 1966-2005 found that the rate of peripartum
hysterectomy due to placenta accreta increased from 5.4% during 1966-1975, to 46.5%
from 1996-2005, an increase of more than 700%, representing a major shift in the profile
of indications for peripartum hysterectomy.(52) Even with aggressive surgical
intervention, maternal death rates in placenta accreta have been reported as high as
7%.(5) Placenta accreta also poses a threat to the infant, mostly due to preterm birth due
to vaginal bleeding or electively to avoid hemorrhage. A survey of 109 cases of placenta
percreta occurring among patients of members of the Society of Perinatal Obstetricians
over a three-year period found a perinatal mortality rate of 9%.(5)
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Public Health Impact

The impact of placenta accreta on public health is also significant. A recent decision
analysis sought to forecast the effect of rising primary cesarean section rates on annual
incidence of previa and accreta. The study reported that if primary and repeat cesarean
rates continue their recent rate of rise, by 2020 the cesarean delivery rate will be 56.2%,
and there will be an additional 6,236 previas, 4,504 accreta, and 130 maternal deaths
annually.(4) Of interest, the study also found that the rise in rates of placenta accreta
trails the rise in cesarean rate by an estimated six years. The findings were consistent
with another model predicting that for every 5% increase in the elective primary CS rate,
will come up to 32 more maternal deaths, 24,000 more surgical complications, and
between $750 million and $1.7 billion in healthcare expenditures.(53)
This concerning data must be considered in light of recent deterioration of maternal
mortality in the United States. From 1998 to 2004, maternal mortality rate in the United
States rose from 10 per 100,000 to 14 per 100,000 live births.(50) Although the reason
for this rise is unclear, the increase in rates of placenta accreta is thought to make a
significant contribution.(6,7,9,40)

Management
It is important to consider both prevention and management so as to minimize the impact
of rising rates of placenta accreta. Optimizing management is receiving a great deal of
attention in the literature. Broad themes include the importance of prenatal diagnosis to
facilitate delivery planning and the crucial role of multidisciplinary care teams. Given
the likelihood of massive hemorrhage and need for cesarean hysterectomy, and
possibility of other complications, pre-delivery planning is essential in cases of suspected
placenta accreta. Scheduled cesarean delivery with a multidisciplinary team and
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measures in place to anticipate possible accreta has been associated with reduced
morbidity, reduced blood loss, and improved outcomes.(1,10,40)

Prevention? A closer look at uterine surgery
Despite our best efforts to optimize management, it is also crucial to focus attention on
ways to avert placenta accreta. With the strong association between previous cesarean
delivery and placenta accreta, and the significant increase in cesarean delivery rates over
the past several decades, cesarean delivery rates are an important target. Modern
cesearean delivery came about in 1926 with the advent of a new surgical approach; this,
coupled with improved use of uterotonics, aseptic technique, and other advances led to
far improved survival rates after cesarean. The rate of cesarean delivery in the US rose
from 5% in 1970 to 25% in 1989 to 32.9% in 2009, or an increase of over 600%.(3) The
rate of vaginal birth after previous cesarean delivery (VBAC) has decreased significantly.
As the VBAC rate declines, for every woman who has a primary cesarean delivery, her
likelihood of having a subsequent cesarean delivery increases, and of developing placenta
accreta.
Cesarean delivery is the most common surgical procedure undergone by women in the
United States. The National Center for Health Statistics estimated that 15% of inpatient
surgeries that took place in the United States in 2001 were cesarean deliveries, or
approximately one million of a total of seven million surgeries.(53) This estimate
underscores the significant implications that cesarean delivery rates have for healthcare
utilization more broadly.
Although cesarean delivery is ubiquitous, it is important to be cognizant of both the
short- and long-term complications. The risk of complications increases with multiple
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cesareans. One study found that women with three or more planned cesarean deliveries
had significantly higher incidence of excessive blood loss (7.9% versus 3.3%; P <.005),
difficult delivery of the neonate (5.1% versus 0.2%; P < .001), and dense adhesions
(46.1% versus 25.6%; P <.001) compared with a group after second cesarean.(50) They
also reported that risk of major complication (uterine rupture, hysterectomy, relaparotomy, bladder or bowel injury, thromboembolism, or excessive blood loss) was
also significantly higher in the repeat cesarean group(8.7% versus 4.3%, P = .013), and
increased with the delivery index number: 4.3%,7.5%, and 12.5% for second, third, and
fourth or more cesarean delivery, respectively (P for trend = .004).(55)
Reasons for increasing rate of cesarean delivery

The reasons for the increase in cesarean rate continue to be a subject of debate. Possible
explanations include increased maternal age, worse maternal health, increased rates of
obesity, maternal preference, provider convenience, and avoidance of legal liability.
With regard to age, Northern Europe has had a similar demographic shift toward
increased maternal age at childbirth without such an increase in cesarean rate.(53) Also,
within the United States cesarean delivery rates have increased across all age groups.(53)
Alternative explanations include patient and provider preference/convenience, avoidance
of legal liability, and malpractice awards; for a small portion of cesarean deliveries, they
may be attributed to a decrease in clinical skills for and change in attitudes toward
operative delivery.(2,3,4,13)
It is certainly the case that there is a crucial role for cesarean delivery. In West Africa,
for example, there is a threshold relationship between the maternal mortality ratio and
cesarean rate: countries or regions with maternal mortality ratios above 450 per 100,000
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typically exhibit CD rates below 1%.(56) The World Health Organization set a target
rate for cesarean delivery of 15%, estimating that 12-15% of deliveries will have a
condition needing intervention, including cesarean.(56) On the opposite end of the
spectrum, the WHO points out that cesarean rates above 15% are accompanied by
increased risk to both mother and baby. Indeed, while cesarean rates in the United States
have increased over recent decades, maternal and neonatal outcomes have not
improved.(13)
In light of concern over high cesarean rates, a few recent studies have sought to elucidate
the clinical situations and indications that precipitate cesarean delivery, including those
marked by variability in clinical thresholds to intervene by cesarean delivery. A recent
study investigated the indications for primary cesarean delivery at Yale-New Haven
Hospital over a seven year period, 2003-2009.(13) They found that the rate of cesarean
delivery increased from 26.0% to 36.5% over that time, equivalent to an increase of 73%;
the rate of repeat cesarean also increased, from 9.8% in 2003 to 14.8% in 2009. The
VBAC rate during the study period dropped from 17.8% to 7.8%. The study reported
that 68% of the increase in primary cesarean rate could be attributed to more subjective
indications, including non-reassuring fetal heart tracing (32%), labor arrest disorders
(including arrest of dilation and arrest of descent; 18%), suspected macrosomia (10%)
and elective per maternal request (8%).(See Fig 2; 13) The study also reported that rates
of cesarean delivery for multiple gestation and preeclampsia increased at rates 200% and
87% higher, respectively, than would be predicted based on population increases in
multiple gestation and preeclampsia.(11)
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Of note, Although rates of cesarean for non-reassuring fetal heart rate have increased
over time, neonatal outcomes have not improved.(52) Several recent studies have
suggested that exercising increased patience in the setting of active phase arrest of labor
could lead to successful vaginal delivery in 33 to 61% of cases.(53)

Fig. 2. Indication for primary cesarean deliveries at Yale-New Haven Hospital,
2003-2009. Adapted from Barber et al 2011.(13)

Summary
Placenta accreta is a growing threat to maternal health, due at least in part to rising rates
of cesarean delivery, with contributions from other uterine surgeries as well. As
antenatal diagnosis and peripartum management improve, secondary prevention of poor
outcomes among women with placenta accreta is more effective. Better provider
preparation and provision of multi-disciplinary peripartum care have been shown to
improve outcomes, but will not help turn the tide of this growing problem. It is important
to seek better understanding of potential modifiable risk factors that may aid in primary
prevention. Among these, recent evidence that a majority of primary cesarean deliveries
at one tertiary care center occurred due to a subjective indication suggests that a
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proportion of these interventions could have been averted without compromising
maternal or fetal health, thereby reducing the number of women who cross that threshold
of increased risk for subsequent accreta. Rates of myomectomy and other surgical
fertility-enhancing management of fibroids have also changed over time. Building a
clearer picture of the rates of and indications for previous uterine surgery may help us not
only better understand and manage this formidable challenge, but also eventually prevent
its further growth.
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Statement of purpose, specific hypothesis, and
specific aims of the thesis
Because placenta accreta is associated with significant maternal and perinatal morbidity
and mortality, it is important to establish the rate of placenta accreta, and profile the risk
factors contributing to placenta accreta over time. To date, there are no documented
efforts to examine the indications for index uterine surgery in women with placenta
accreta.
In this study, we will retrospectively determine the rate of placenta accreta at Yale-New
Haven Hospital from 1996 to 2011 and the indications for index uterine surgery in these
patients, in order to meet three aims:
Aim 1: To determine the rate of placenta accreta at Yale-New Haven Hospital over the
period of 1996 to 2011.
Aim2: To determine the rate of previous uterine surgery exposure among patients with
placenta accreta.
Aim 3: To determine the rate of index cesarean deliveries due to subjective indications in
patients with placenta accreta.
Analysis will include a retrospective examination of indication for primary uterine
surgery by year of accreta diagnosis, including calculating change in rates of placenta
accreta associated with a given indication over time, based on number of all births at
YNHH in a given year. We will also analyze indication for index uterine surgery, and
plan to calculate proportion of uterine surgeries due to each indication, to compare for
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change in proportion over time. Finally, the analysis will include presence of other risk
factors, including number of cesarean deliveries or other uterine surgeries, maternal age,
and comparison of outcomes by risk exposure. Results from this study will inform a
future extension of the project, to incorporate a control group for comparison.
Establishing whether the rate of placenta accreta is increasing at Yale-New Haven
Hospital, whether the profile of patient outcomes has shifted over time, and gaining a
better understanding of the indications for which women are receiving first exposure to
uterine surgery will demonstrate the degree to which cesarean section versus other uterine
surgery is the index exposure in this group of patients with placenta accretaAmong
cesarean deliveries, documenting the rate of more subjective indications and the change
in this rate over time may provide evidence that at least a proportion of placenta accreta
have the potential to be safely averted. It may also help emphasize the need for further
research on management of more subjective indications for cesarean delivery, including
non-reassuring fetal heart tracing, suspected macrosomia, and labor arrest disorders, to
optimize both maternal and neonatal outcomes.
We hypothesize that rate of placenta accreta has increased over the study duration, and
that a majority of patients will have previous uterine surgery exposure. Of those with
previous uterine surgery exposure, we anticipate that a significant proportion will have
received their index exposure to cesarean delivery for subjective indications, including
non-reassuring fetal heart tracing, arrest of labor, suspected macrosomia and elective per
maternal request.
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Methods
The group of patients with histopathologic diagnosis of placenta accreta at Yale-New
Haven Hospital from January 1995 to December 2011 was generated via query of the
database maintained by the Department of Surgical Pathology. Query of all pathology
reports that include text of ‘accreta’, ‘acreta’, ‘percreta’ or ‘increta’ from January 1995 to
December 2011 returned a total of 249 cases with a diagnosis of abnormal placentation.
Data on all births at Yale-New Haven Hospital were available for July 1996 through
December 2011, based on obstetric department records kept monthly by an obstetric
department nurse administrator. This data formed the basis for analysis in the recent
investigation of indication for cesarean delivery at Yale-New Haven Hospital,(13)
improving our ability to compare findings between these two studies. Hence, we decided
to exclude cases of accreta occurring between January 1995 and June 1996 (n=22) from
analysis of accreta trends, rather than augment with a different source of data for baseline
birth rate.
For purposes of evaluating diagnostic consistency, cases of placenta accreta were also
identified via query of International Classification of Disease-9 (ICD-9) codes from
hospital billing records. ICD-9 codes 666.0 or 667.0 designate retained placenta with and
without hemorrhage, including primary or secondary diagnosis of placenta accreta with
and without hemorrhage. This query generated a list of 802 cases from n October 1995
(earliest available date) to December 2011.
Comparison of the pathology-confirmed and ICD-9-based patient pools to examine
diagnostic methods revealed significant discrepancy. Of the 249 cases of placenta
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accreta diagnosed by histopathology, which is often taken to be the gold standard for
diagnosis of placenta accreta, 173 (69.5%) were not captured in the ICD-9 code query. A
sample of cases from the ICD-9 query (20 randomly selected, 20 selected for clinical
features consistent with placenta accreta) were reviewed for pathology findings, and did
not return any additional cases of pathology-confirmed placenta accreta. In addition,
review of 82 randomly selected cases of the ICD-9 query revealed 17 cases (20.7%) that
were consistent with placenta accreta by pathology. There were numerous cases of mild
retained placenta as well as normal deliveries that lacked a clear indication for their
coding. This data translates to a sensitivity of 31% and specificity of 99% for the
identification of cases of placenta accreta by ICD-9 code compared with actual cases
identified by histopathology (positive predictive value 9% and negative predictive value
99%). In this sample, with a prevalence of placenta accreta of 0.34%, the high specificity
and high negative predictive value are essentially meaningless, and the low sensitivity
and low positive predictive value reflect the inadequacy of using ICD-9 code to capture
cases of placenta accreta. These findings demonstrated that at our institution, ICD-9 code
query cannot be relied upon to return all cases of placenta accreta; therefore clinical
diagnosis through ICD9 code query was excluded as a means to establish this group of
patients. Thus, in this study we opted to restrict case inclusion to confirmed
histopathologic diagnosis. A total of 100 cases of non-focal accreta were included in the
final analysis. These cases were compared to the 122 cases of focal accreta in the
descriptive results.
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Fig. 3. Cases of placenta accreta diagnosed by pathology at Yale-New Haven
Hospital, 1995-2011.
Of the 249 cases of placenta accreta diagnosed via histopathology, cases were divided
between focal accreta, accreta vera, increta and percreta.(Fig. 3) In this paper, placenta
accreta will be used as the general term for all types of placenta accreta, while the
specific type of abnormal placentation will be designated focal placenta accreta, placenta
accreta vera, increta or percreta; the latter three types will collectively be referred to as
non-focal accreta. Two cases were excluded from the analysis because the patient chart
had been lost. There were three patients who each had two cases of diagnosed accreta.
For these patients, the second instance of accreta was included in study analysis, and first
was excluded. Of the 244 remaining patients with placenta accreta, 22 cases that
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occurred from January 1995 through June 1996 were excluded from analysis because
birth data was not available for that time period. A total of 122 cases of focal placenta
accreta and 100 cases of non-focal accreta were used in the current analysis. Non-focal
accreta cases consisted of: 63 cases of placenta accreta vera, 23 cases of placenta increta
and 14 cases of placenta percreta. The 122 cases of focal placenta accreta were analyzed
separately for patient characteristics and outcomes, because of varying sensitivity in
diagnosis of focal accreta. The Yale University Human Investigations Committee
approved this protocol.
Each patient chart was reviewed to determine obstetric history, indication for all previous
cesarean deliveries, and maternal and perinatal care and outcomes for the accreta
pregnancy. All index cesarean deliveries were categorized as one of the following
indications, based on the classification used by Barber et al: non-reassuring fetal heart
tracing; labor arrest disorders (arrest of dilation or descent, including failed vacuum or
failed forceps); suspected macrosomia; elective per maternal request; malpresentation;
multiple gestation; preeclampsia, ecclampsia (including eclampsia and HELLP cases);
other maternal or fetal indications; and other obstetric indications.(13) Suspected
macrosomia was defined by the provider based on either an ultrasound-derived estimated
fetal weight or a clinical estimated fetal weight. General practice has been a threshold of
5,000g in non-diabetic patients, and 4,500g in diabetic patients. Elective indication was
defined as elective per maternal request, in absence of medical indication.
Malpresentation represents breech presentation, face presentation, transverse lie, and
unstable lie. Preeclampsia, eclampsia, and hemolysis, elevated liver enzymes, and low
platelets syndrome are represented in a distinct category because of their higher
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frequency. Other maternal indications are defined as other maternal conditions predating
the pregnancy that could complicate delivery (e.g., maternal malignancy, maternal human
immunodeficiency virus). Fetal indications include antenatal problems preceding the
intrapartum period (e.g., fetal anomalies and intrauterine growth restriction). Other
obstetric indications include conditions brought about by the presence of the current
intrauterine pregnancy (e.g., placental abruption, accreta, previa, and cord prolapse).
Indications designated as ‘subjective’ included: non-reassuring fetal heart tracing, labor
arrest disorders, suspected macrosomia and elective by maternal request. There were five
patients for whom the indication for index cesarean delivery was unavailable. In cases
where more than one indication for cesarean delivery was present, the indication that
most directly caused the plan of care to shift to cesarean delivery was used.
Based on convention at YNHH, pregnancies recorded in the patient chart as ‘TAB’ were
assumed to have a dilation & curettage (D&C) unless otherwise specified. All dilation &
curettage procedures were counted as part of the total number of uterine surgeries, with
the exception of a curettage done as part of a more extensive uterine surgery, in which
case it was accounted for as part of that surgery. In several cases, the type of abortion in
a patient’s obstetric history was not specified. Such cases are included in the total
number of abortions, but not categorized as spontaneous or induced. For pregnancy
terminations recorded as occurring during the first trimester, the gestational age was
recorded as 12 weeks. ‘Full term’ pregnancies were recorded as occurring at a
gestational age of 40 weeks.
For the 16 patients (focal accreta, n=12; accreta, n= 4) whose estimated blood loss during
the accreta delivery was listed as ‘normal,’ a volume was assigned based on average
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values reported in the literature: 300mL for vaginal birth,1 and 600mL for Cesarean
delivery.2 Estimated blood loss was not noted for 23 patients, which were excluded from
analysis of blood loss. In case of autologous blood transfusion, 1 unit was assumed to be
~220mL to calculate units of autologous blood when volume was reported in mL.
Tobacco use was analyzed by any previous smoking (yes/no) and smoking during accreta
pregnancy (yes/no). Availability of data on quantity of tobacco use was insufficient to
stratify by intensity of use. Second-hand smoke exposure was not counted as smoking
exposure. Medication use and presence of co-morbidities were recorded primarily as a
proxy for maternal health status.
For the study, Daniel Bercik performed chart review on 20% of the cases. Regression
analysis was performed by Jessica Illuzzi, MD, MS.
Demographic characteristics, including age, gravidity, parity, race, obstetric history, and
maternal and perinatal outcomes of mothers with and without previous exposure to
uterine surgery were compared. Rates of placenta accreta were calculated annually as
the number of cases of placenta accreta per 1,000 births, and stratified by focal and nonfocal accreta cases. Because several accreta pregnancies ended in fetal demise, rates
were calculated based on data for all births, rather than live births. Patient categorical
characteristics were compared using chi-square analysis, except where small number of
observations necessitated use of Fisher’s exact test. Continuous variables (e.g. estimated
blood loss) were analyzed using t-test for focal/non-focal and ANOVA for comparison of

1

Average estimated blood loss (EBL) for vaginal delivery: 287mL, based on findings of 2 studies cited in
Begley et al 2011, and consistent with other published estimates.(55)
2
Average EBL for cesarean delivery: 592 +/- 222mL as estimated by obstetricians, in audit of 126 patients
delivered by cesarean.(56)
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accreta vera, increta and percreta. Logistic regression was done to analyze the primary
outcome of rate of placenta accreta by primary exposure variable of indication for
cesarean delivery (e.g. objective versus subjective), using time period as the predictive
variable. Indications for index uterine surgery were analyzed by logistic regression and
cumulative annualized relative risk increase (e.g. odds ratio compounded annually over
the duration of the study period; shows the increase in risk for a patient over the duration
of the study period). Statistical analysis was performed using SAS 9.2.
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Results
Patient characteristics
Comparison between focal and non-focal accreta

Characteristics of patients with focal and non-focal accreta as well as among those with
placenta accreta, increta and percreta are compared in Table 1. Comparing the 100
patients with non-focal accreta with the 122 cases of focal accreta, there was a significant
difference in age and gravidity;there were no significant differences in race/ethnicity,
parity average number of previous cesearean deliveries, and rate of concurrent placenta
previa.(Table 1) Grand multiparous women (with ≥ 5 previous births of > 20 weeks
gestation) made up 3% of cases. (Data not shown) Overall rate of co-morbidities appear
to be higher among focal accreta versus no-focal accreta (p=0.04), including
hysterectomy ICU admission, rate of transfusion, estimated blood loss, units of red blood
cells transfused, and duration of hospital stay after delivery. There was one woman with
increta who did not undergo hysterectomy. She was a 37-year old G6P1132 who had a
previous histologically-confirmed placenta accreta vera in her third pregnancy, which
was followed by myometrial resection and repair of the area of the accreta; at the time of
the increta pregnancy, she had had a total of three previous cesarean deliveries, one
previous curettage, and two previous myomectomies. In the increta pregnancy, she had
1L of blood loss, and underwent wedge resection of placenta and adjacent large uterine
window on anterior wall. She had no complications and did not need blood transfusion.
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Non‐focal
Focal accreta
(n=122)
32.1 {6.3}

Age
Race
Black
Hispanic
White
Other

B

A

accreta
(n=100)
33.9 {5.2}

p
0.023
0.107

Accreta vera
(n=63)
33.3 {4.7}

Increta (n=23) Percreta (n=14)
36.2 {4.3}
33.1 {7.5}

p
0.060
0.383

29 (23)
15 (12)
69 (57)

14 (14)
10 (10)
72 (72)

10 (16)
5 (8)
46 (73)

2 (9)
3 (13)
18 (78)

2 (14)
2 (14)
8 (57)

9 (7)

4 (4)

2 (3)

0 (0)

2 (14)

25 (20)
18 (15)

14 (14)
7 (7)

0.206
0.069

7 (11)
1 (2)

3 (13)
2 (9)

4 (29)
4 (29)

0.260
0.003

0.005
0.0003

3 (2‐4)
1 (0‐2)

4 (2‐5)
1 (1‐2)

5.5 (4‐7)
2 (1‐3)

0.001
0.316

Smoking
Ever
Current
Obstetrical history
Gravidity
Parity
Uterine surgery
Cesarean deliveries (#)
Curettage (#)
Other uterine surgery (#)
Multiple gestation
IVF (during accreta pregnancy)
Placenta previa
Comorbidities

C

D

E

3 (2‐4)
1 (0‐1)

3 (2‐5)
1 (0‐2)

0.27 {0.55}
0.75 {1.12}

1.05 {1.13}
0.93 (1.91}

<0.0001
0.397

0.78 {1.02}
0.7 {1.06}

1.22 {1.0}
0.78 {1.0}

2.00 {1.3}
2.21 {4.34}

0.001
0.024

0.1 {0.42}
22 (18)
13 (10)
13 (10)

0.25 {0.6}
6 (6)
10 (10)
45 (45)

0.042
0.007
0.873
<0.0001

0.26 {0.66}
5 (8)
7 (11)
22 (35)

0.32 {0.57}
0 (0)
2 (9)
13 (57)

0.07 {0.27}
1 (7)
1 (7)
10 (71)

0.461
0.459
1.000
0.021

88 (72)

59 (59)

0.040

34 (59)

14 (61)

11 (79)

0.234

Preeclampsia or hypertension
DM
Obesity
Medications
Age >= 35 years
Substance abuse
Asthma
Asherman's syndrome
Outcomes
Maternal
Hysterectomy
Multiple cases of accreta
ICU admission
Transfused
Estimated blood loss (L)

36 (30)
21 (17)
9 (7)
40 (33)
49 (40)
7 (6)
12 (10)
2 (2)

17 (17)
14 (14)
7 (7)
25 (25)
44 (44)
6 (6)
9 (9)
4 (4)

0.030
0.513
0.914
0.205
0.564
0.934
0.832
0.413

8 (17)
7 (14)
4 (7)
11 (25)
24 (44)
2 (6)
3 (9)
4 (4)

5 (22)
2 (9)
2 (9)
8 (35)
16 (70)
2 (9)
4 (17)
0 (0)

4 (29)
5 (36)
1 (7)
6 (43)
4 (29)
2 (14)
2 (14)
0 (0)

0.241
0.077
0.859
0.065
0.015
0.105
0.108
0.607

7 (6)
0 (0)
7 (6)
18 (15)
0.9 {0.9}

68 (68)
3 (3.0)
42 (42)
61 (61)
3.6 {5.2}

<0.0001
0.090
<0.0001
<0.0001
<0.0001

34 (54)
2 (3)
19 (30)
29 (46)
2.5 {4.3}

22 (96)
1 (4)
12 (52)
19 (83)
4.6 {6.3}

14 (100)
0 (0)
11 (79)
13 (93)
6.9 {5.4}

0.0004
1.000
0.002
0.0003
0.007

Units of pRBCs transfused

4.1 {3.0}

10.2 {7.4}

<0.0001

8.9 {6.4}

9.7 {8.6}

13.9 {6.8}

0.125

4.6 {2.2}

7.0 {7.4}

0.002

6.1 {5.2}

6.7 {3.6}

11.9 {15.3}

0.028

36.7 {5.0}

34.8 {7.2}

0.006

34.8 {5.9}

33.1 {6.0}

27.8 {11.0}

0.004

7 (70.)
4 (28.6)
0 (0)

0.210
0.382
0.152

Duration of hospital stay after
delivery (days)
Perinatal
Gestational age
Gender
F
Baby to NICU
Intrauterine fetal demise
Baby weight (g)

70 (59.8)
53 (43.4)
2 (1.6)

42 (47.2)
36 (36.)
4 (4.0)

0.071
0.260
0.413

27 (47.4)
21 (33.3)
4 (6.4)

8 (36.4)
11 (47.8)
0 (0)

2624 {925}
2641 {752}
0.899
2866 {617}
2406 {617}
2103 {965}
0.008
Data presented as n(%) for discrete variables, mean {SD} for continuous variables, median (inter‐quartile range) for gravidity and parity. Chi‐square
test used except where n was too small; Fisher's Exact test was then used instead.
A

Includes accreta, increta and percreta

B

Includes American Indian, Asian and Other.
Includes myomectomy, septum resection, lysis of uterine adhesions, endometrial ablation and polypectomy

C
D

Recorded primarily as a proxy for maternal health status.

E

Any previous diagnosis of preeclampsia, ecclampsia or hemolysis, elevated live enzymes, low platelets syndrome, or hypertension.

F

Excluded from data collection were: nifedipine, prometrium, 17‐OHP, prenatal vitamins, iron, albuterol, and common non‐prescription medications
that are approved in pregnancy (e.g. acetaminophen).

Table 1. Patient characteristics by type of placenta accreta.
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Comparison between accreta vera, increta and percreta

Between types of accreta, there was no significant difference in average age or parity at
accreta delivery. There was a significant difference among rate of smoking during the
accreta pregnancy, gravidity, number of previous cesarean deliveries, and placenta
previa. Maternal outcomes were significantly more severe among percreta cases in
comparison with accreta vera cases in regard to: hysterectomy (92.9% versus 54%; p =
0.0004); ICU admission (78.6% versus 30.2%; p = 0.002); transfusion (92.9% versus
46.0%; p = 0.0003); estimated blood loss (6.94 L versus 2.47 L; p = 0.007) and duration
of hospital stay after delivery (11.9 days versus 6.1 days; p = 0.028). Outcome among
neonates also differed significantly between types of accreta.

Description of accreta trends, with focal accreta
included
From July 1996 to December 2011, a total of 72,845 births occurred at Yale-New Haven
Hospital (including still births). During that time, there were a total of 222 patients with
placenta accreta diagnosed by histopathology, which is a rate of 3.05 cases per 1,000
births.(Table 2) This total includes 122 cases of focal placenta accreta (1.67 per 1,000
births), 63 cases of placenta accreta vera (0.86 per 1,000 births), 23 cases of placenta
increta (0.32 per 1,000 births), and 14 cases of placenta percreta (0.19 per 1,000 births).
To reduce the influence of annual variation, analysis was done by 3-year periods, with the
exception of 3.5-year period from July 1996 – December 1999.
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A

Year

All births
E

B

Focal accreta

Non‐focal
accreta

C

Accreta vera

Increta

Percreta

All accreta

D

17,244

3 (.17)

17 (.99)

13 (.75)

3 (.17)

1 (.06)

20 (1.16)

2000‐2002

14,164

17 (1.2)

20 (1.41)

17 (1.2)

2 (.14)

1 (.07)

37 (2.61)

2003‐2005

14,353

33 (2.3)

19 (1.32)

10 (.7)

7 (.49)

2 (.14)

52 (3.62)

2006‐2008

13,864

62 (4.47)

21 (1.51)

15 (1.08)

3 (.22)

3 (.22)

83 (5.99)

2009‐2011

13,220

7 (.53)

23 (1.74)

8 (.61)

8 (.61)

7 (.53)

30 (2.27)

Total

72,845

122 (1.67)

100 (1.37)

63 (.86)

23 (.32)

14 (.19)

222 (3.05)

1996‐1999

A

Of accreta delivery

B

Live and still births

C

Denotes accreta, increta and percreta.

D

Focal and non‐focal accreta.

E

Time period includes July 1996‐Dec 2011. The other four time periods are each three calendar years.

Data presented as n (rate per 1,000 births)

Table 2. Rates of histologically-diagnosed placenta accreta by type

Over this time period, the rate of placenta accreta including all cases varied considerably,
from a nadir of 1.16 in per 1,000 births in 1996-1999 to a peak of 5.99 per 1,000 births in
2006-2008, with a subsequent sharp decline to 2.27 per 1,000 births in 2009-2011. (Fig.4)

Fig. 4. Rate of all cases of placenta accreta, per 1,000 births. Error bars reflect standard
error of the mean.
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It would be surprising for the rate of placenta accreta to have a precipitous drop to less
than half of its previous rate from one 3-year period to the next. The potential influences
on this trend are more apparent when the cases are divided by type of accreta: a similar
pattern is noted in cases of focal placenta accreta: rising from 0.17 per 1000 births in
1996-1999 to 4.47 per 1,000 births in 2006-2008, followed by a decline to a rate of 0.53
per 1,000 births in 2009-2011. (Fig. 5)

Fig. 5. Rate of focal placenta accreta, per 1,000 births. Error bars represent standard
error of the mean.

One possible contributor to this trend is suggested by the pattern of diagnosis of focal
placenta accreta by two particular pathologists: among 18 pathologists who diagnosed
accreta over the study period, 84% of cases were diagnosed by two pediatric pathologists
with expertise in the placenta, with a rise in diagnosed focal placenta accreta cases of two
to three-fold between 2005-2009. The possible influence of interpathologist variability
on diagnosis rates is further underscored by the fact that the decline in rate of focal
accreta diagnosis occurred at the time of their departure from Yale-New Haven Hospital
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to other institutions. The decline in rate of focal accreta diagnosis roughly corresponds to
the timing of their two departures in 2008 and 2009, as indicated below on the graph of
focal accreta diagnosis by year.(Fig. 6) Both of the pathologists had been present prior to
this increase, and attribute it to an increase in emphasis on diagnosis of focal accreta in
the literature and pathology conferences. (Personal communication with Miguel Reyes
Mugica MD and Brian West MD, March 7, 2012). The diagnosis pattern at our
institution suggests that there are varying thresholds for the diagnosis of focal accreta
among some pathologists. Studies have shown that pathologists without specialization in
placental pathology have a high rate of underdiagnosis.(61)

Fig. 6. Rate of focal placenta accreta by year. Arrowheads depict the timing of departure
of the two pathologists responsible for 84% of diagnoses of focal placenta accreta across the
study time period. Pathologist 1 departed in mid-2007, and pathologist 2 departed in late
2008.

The presence of this correlation suggests that the sensitivity of diagnosis for focal accreta
at Yale-New Haven Hospital may have fluctuated over time.. Although there are likely
other influences also underpinning the fluctuations in rate of focal accreta over the study
period, we felt this fluctuation warranted separation of data for focal placenta accreta
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from data for accreta vera, increta and percreta. Thus, the focal accreta cases were
analyzed separately and excluded from analysis of trends in rate of incidence and
exposure to previous uterine surgery.

Exposure to uterine surgery among non-focal accreta
cases
Among patients with non-focal accreta, there was a significant difference between rate of
exposure to index uterine surgery (p = 0.039); see Table 3. Among women with accreta
vera, 42.9% had cesarean delivery as their index exposure, 20.6% had D&C, 12.7% had
other uterine surgery (including myomectomy, septum resection, lysis of adhesions,
endometrial ablation and polypectomy), and 23.8% had no previous uterine surgery
exposure. Index surgeries among women with increta were cesarean delivery in 65.2%
of women, D&C among 13%, other uterine surgery among 17.4% and no uterine surgery
among 4.4%. Among women with percreta, index surgery was cesarean delivery in
85.7%, D&C in 7.1%, other uterine surgery in 7.1%; there were no women with percreta
who did not have a previous uterine surgery exposure. Specific previous uterine surgery
varied significantly by type of non-focal accreta (p = 0.042). Sixty-four percent of
women with percreta cases had been exposed to more than one type of uterine surgery
(e.g. had a history of cesarean delivery, D&C and/or other uterine surgery), in contrast to
47.8% of women with increta and 22.2% of women with accreta vera (p = 0.042). On
average, women with accreta vera had 1.73 previous uterine surgeries (of any type; SD
1.53); women with increta had an average of 2.0 previous uterine surgeries (SD 1.4), and
women with percreta had an average of 4.36 previous uterine surgeries (SD 4.33; p =
0.0003).

39

Accreta vera
(n=63)
Index uterine surgery type
Cesarean delivery
D&C
A

Other
None

Previous types of uterine surgery
Cesarean delivery only
Curettage only
Other uterine surgery only
A,B

>1 type of uterine surgery
None
Total number of previous
uterine surgeries

Increta (n=23)

p
0.039

Percreta (n=14)

27 (43)
13 (21)

15 (65)
3 (13)

12 (86)
1 (7)

8 (13)
15 (24)

4 (17)
1 (4)

1 (7)
0 (0)

17 (27)
13 (21)
15 (24)

7 (30)
3 (13)
1 (4)

3 (21)
2 (14)
0 (0)

14 (22)
15 (24)

11 (48)
1 (4)

9 (64)
0 (0)

0.042

1.73 {1.53}

2 {1.4}

4.36 {4.33}

0.0003

Data presented as n(%) for discrete variables or mean {SD] for continuous variables. Chi‐square used
except where n was too small; Fisher's Exact test was then used.
A

Includes myomectomy, septum resection, lysis of uterine adhesions, endometrial ablation and
polypectomy

B

More than one of: CS, D&C/curettage or other uterine surgery.

Table 3. Patient characteristics: exposure to uterine surgery among non-focal accreta cases.

Trend in non-focal accreta rate
The overall rate of non-focal placenta accreta at Yale-New Haven Hospital between July
1996 and December 2011 was 1.37 per 1,000 births.(Table 2) The rate of all non-focal
cases increased from 0.99 per 1,000 births to 1.74 per 1,000 births, with an average
increase of 12.4% per 3-year period (95% CI -1.6 – 28.5%). (Table 4, Fig. 7)

40

1996‐

A

Year

1999

B

2000‐
2002

2003‐
2005

2006‐
2008

2009‐2011

Mean 3‐year Period
Increase [%(95% CI)]

Cumulative Risk (95%
p value
CI)

Type of placenta accreta
Focal
Non‐focal accreta

C

0.17

1.20

2.30

4.47

0.53

31.6% (16.1 ‐ 49.2%)

3.95 (2.11 ‐ 7.4)

<.0001

0.99

1.41

1.32

1.51

1.74

12.4% (‐1.6 ‐ 28.5%)

1.79 (0.92 ‐ 3.5)

0.0854
0.7046

Accreta vera

0.75

1.20

0.70

1.08

0.61

‐3.2% (‐18.1 ‐ 14.4%)

0.85 (0.37 ‐ 2.0)

Increta

0.17

0.14

0.49

0.22

0.61

33.0% (‐0.3 ‐ 78.3%)

4.16 (0.99 ‐ 18.0)

0.0526

Percreta

0.06

0.07

0.14

0.22

0.53

81.9% (17.3 ‐ 182%)

19.9 (2.22 ‐ 179)

0.0075

22.4% (11.8 ‐ 34.1%)

2.75 (1.75 ‐ 4.3)

<.001

All placenta accreta D

1.16

2.61

3.62

5.99

2.27

A

Of accreta delivery
Time period includes July 1996‐Dec 2011. The other four time periods are each three calendar years.
C
Includes accreta, increta and percreta
B

D

Includes focal and non‐focal accreta

Table 4. Change in rate of non-focal placenta accreta over time, per 1,000 births

Fig. 7. Rate of non-focal accreta, per 1,000 births. Error bars represent standard
error of the mean.

The rate of placenta accreta vera did not change significantly, with a slight decrease of 3.2% per 3-year period (95% CI -18.1% – 14.4%), whereas the rate of placenta increta
increased from 0.17 to 0.61 per 1,000 births, or 33.0% per 3-year period (95% CI -0.3% –
78.3%).(Fig. 8) The cumulative risk of placenta accreta vera over this time period was
0.85 (95% CI 0.37 – 2.0); for increta, it was 4.16 (95% CI 0.99 – 18.0). The rate of
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placenta percreta increased from 0.06 to 0.53 per 1,000 births, or 81.9% per 3-year period
(95% CI 17.3% – 182%), for a cumulative risk of 2.75 (95% CI 1.75 – 4.3) over the study
period.

Fig. 8. Rate of non-focal placenta accreta by type, per 1,000 births. Error bars
represent standard error of the mean.

Association between exposure to index uterine surgery
and risk of non-focal accreta
Among women with non-focal accreta, index exposure to uterine surgery was cesarean
delivery for 54 (54%) patients, dilation & curettage for 17 (17%) patients, and other
uterine surgery for 13 (13%) patients.(Table 5) Other uterine surgery includes
myomectomy, septum resection, lysis of uterine adhesions, endometrial ablation and
polypectomy. There were 16 patients for whom there was no known exposure to uterine
surgery. This analysis was not completed for the cases of focal accreta, due to the
variable sensitivity of diagnosis over the study period (see methods, above).
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A

Year

Non‐focal
accreta

CS

OUS

D&C

No uterine
surgery

1996‐1999 B

17

(0.99)

7 (0.41)

2 (0.12)

4 (0.23)

4 (0.23)

2000‐2002

20

(1.41)

8 (0.56)

1 (0.07)

6 (0.42)

5 (0.35)

2003‐2005

19

(1.32)

14 (0.98)

1 (0.07)

2 (0.14)

2 (0.14)

2006‐2008

21

(1.51)

12 (0.87)

1 (0.07)

3 (0.22)

5 (0.36)

2009‐2011
Total

23
100

(1.74)
(1.37)

13 (0.98)
54 (0.74)

8 (0.61)
13 (0.18)

2 (0.15)
17 (0.23)

0 (0.00)
16 (0.22)

A

Of accreta delivery

B

Time period includes July 1996‐Dec 2011. The other four time periods are each three calendar years.

CS ‐ cesarean section; OUS ‐ other uterine surgery (myomectomy, endometrial ablation, septum resection; excluding
cesarean and curettage); D&C ‐ D&C or other curettage
Data presented as n (rate per 1,000 births)

Table 5. Non-focal accreta by index exposure to uterine surgery: n (rate per 1,000
births)

Over the study period, the rate of placenta accreta with cesarean delivery as index uterine
surgery among all births increased from 0.41 per 1,000 births to 0.65 per 1,000 births; the
proportion of women with placenta accreta and D&C as index exposure decreased from
0.23 per 1,000 births to 0.15 per 1,000 births.(Table 5) Rate of accreta and other uterine
surgery (OUS) as index exposure changed over time from 0.12 per 1,000 births in 19961999 to 0.07 per 1,000 births in 2000-2008, to 0.61 per 1,000 births in 2009-2011. Rate
of non-focal placenta accreta and previous uterine surgery exposure declined from 0.23
per 1,000 births to 0 per 1,000 births.
Among women with non-focal placenta accreta, index uterine surgery exposure was
cesarean delivery for 54 patients; 27 (50%) of these patients underwent surgery for a
subjective indication (Table 6, Fig. 9). Nineteen (35%) of these patients had an objective
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indication for primary cesarean delivery. Subjective indications included non-reassuring
fetal heart tracing, labor arrest disorder, suspected macrosomia and elective per maternal
request in absence of medical indication. Another 5 (9%) of patients had an unknown
indication for primary cesarean, and 3 (6%) of patients had preeclampsia listed as the
indication for uterine surgery.

A

All CS

Year

G

B

Subjective

C

Objective

D

Unknown

E

PEC

F

7 (0.41)

5

(0.29)

1 (0.06)

1 (0.06)

0 (0.)

2000‐2002

8 (0.56)

3

(0.21)

4 (0.28)

0 (0.)

1 (0.07)

2003‐2005

14 (0.98)

7

(0.49)

5 (0.35)

2 (0.14)

0 (0.)

2006‐2008

12 (0.87)

7

(0.5)

4 (0.29)

0 (0.)

1 (0.07)

2009‐2011

13 (0.98)

5

(0.38)

5 (0.38)

2 (0.15)

1 (0.08)

Total

54 (0.74)

27

(0.37)

19 (0.26)

5 (0.07)

3 (0.04)

1996‐1999

A

Of accreta delivery

B

Sum of subjective, objective, unknown and preeclampsia cases.

C

Includes non‐reassuring fetal heart tracing, labor arrest disorder, suspected macrosomia, and
elective per maternal request (with no medical indication).

D

Includes malpresentation, multiple gestation, maternal/fetal and obstetric indications.

E

Includes cases with indication cited as unknown.

F

Preeclampisa is not an indication for cesarean delivery, but often no other reason is cited in records.

G

Time period includes July 1996‐Dec 2011. The other four time periods are each three calendar
years.

CS ‐ cesarean section; PEC ‐ preeclampsia

Table 6. Cases of non-focal accreta with cesarean section as index uterine surgery
exposure, by indication for index primary cesarean: n (rate per 1,000 births)
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Fig. 9. Rate of accreta among women with cesarean section as index uterine surgery
exposure, by indication for cesarean.

The data can also be considered based on rate of accreta associated with cumulative
exposure to uterine surgery (e.g. all uterine surgeries prior to accreta pregnancy) either
total number of exposures (with all exposures taken as equal), or by type of exposure
(e.g. cesarean only, uterine surgery & curettage, etc). The overview of this data is
depicted in Fig. 10A-B. Based on total number, 22% had one known uterine surgery;
26% of cases had 2 previous uterine surgeries, 18% had 3 and 18% had 4 or greater. Of
course, 16% of women still had no prior uterine surgery exposure. Based on type of
uterine surgery exposure (but not taking into account frequency), for 18% of women,
curettage was their only known surgical exposure; for 27% of women it was cesarean
delivery alone (1 or more); 5% of women had another uterine surgery as their only
surgical exposure. Twenty-two percent of patients had at least one of each cesarean and
curettage; 5% of patients had all three types of uterine surgery exposure.
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Fig. 10A.

Fig. 10B.

Fig. 10A-B. Cumulative exposure to previous uterine surgery. A. By total number
of previous uterine surgeries, including cesarean section, curettage and other
uterine surgeries. B. By types of uterine surgery.
Among the four categories of exposure to previous uterine surgery, there was a
significant increase over the study period in the likelihood of cesarean delivery and other
uterine surgery as types of index exposure to uterine surgery among women with nonfocal placenta accreta.(Table 7) The rate of cesarean delivery as the index uterine
surgery increased by 21.9% per 3-year period (95% CI 1.4% - 46.6%). This translated to
a cumulative risk of 2.69 (95% CI 1.07 – 6.8), meaning that among all births over the
duration of the study, women were 2.69 times more likely to have an accreta in the
setting of a prior index cesarean delivery at the end of the study period (2009-2011)
compared to the beginning (1996-1999). For other uterine surgery, the average increase
over each 3-year interval was 71.1% per 3-year period (95% CI 10.4% - 165%), with a
cumulative risk of 14.66 (95% CI 1.64 - 131). The rates of curettage and for no previous
exposure to uterine surgery did not change significantly. There was no significant change
in the rate of non-focal placenta accreta associated with any of the indications for
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cesarean delivery: subjective, objective or unknown, though the rates of each increased
slightly. Subjective indication increased slightly, at 13.2% per 3-year period (95% CI 12.4% - 46.4%), objective indication increased by 30.4% per 3-year period (95% CI 5.1% - 79.1%). Preeclampsia was included as a separate category; although it is not an
absolute indication for cesarean delivery, it is often noted as such with no other data
available.

1996‐

A

Year

1999

B

2000‐
2002

2003‐
2005

2006‐
2008

2009‐2011

Mean 3‐year Period
Increase [%(95% CI)]

Cumulative Risk (95%
p value
CI)

Index uterine surgery exposure

Cesarean delivery

0.41

0.56

0.98

0.87

0.98

21.9% (1.4 ‐ 46.6%)

2.69 (1.07 ‐ 6.8)

0.0352

Curettage

0.23

0.42

0.14

0.22

0.15

‐12.8% (‐37.0 ‐ 20.8%)

0.50 (0.10 ‐ 2.6)

0.4110

Other uterine surgery C

0.12

0.07

0.07

0.07

0.61

71.1% (10.4 ‐ 165%)

14.66 (1.64 ‐ 131)

0.0163

No uterine surgery

0.23

0.35

0.14

0.36

0.00

‐16.4% (‐40.5 ‐ 17.3%)

0.41 0.07 ‐ 2.2)

0.2993

Indications for cesarean delivery

Subjective D

0.29

0.21

0.49

0.50

0.38

13.2% (‐12.4 ‐ 46.4%)

1.86 (0.52 ‐ 6.7)

0.3433

Objective

E

0.06

0.28

0.35

0.29

0.38

30.4% (‐5.1 ‐ 79.1%)

3.77 (0.77 ‐ 18.4)

0.1014

Preeclampsia

F

0.00

0.07

0.00

0.07

0.08

49.0% (‐36.0 ‐ 247%)

7.34 (0.11 ‐ 501)

0.3549

Unknown indication G

0.06

0.00

0.14

0.00

0.15

27.5% (‐31.0 ‐ 136%)

3.37 (0.16 ‐ 72.4)

0.4385

A

Of accreta delivery
B
Time period includes July 1996‐Dec 2011. The other four time periods are each three calendar years.
C

Includes myomectomy, septum resection, lysis of uterine adhesions, endometrial ablation and polypectomy

D

Includes non‐reassuring fetal heart tracing, labor arrest disorder, suspected macrosomia, and elective

E

Includes malpresentation, multiple gestation, maternal/fetal and obstetric indications.

F

Preeclampisa is not an indication for cesarean delivery, but often no other reason is cited in records.
Includes cases with indication cited as unknown.

G

Table 7. Rate of non-focal placenta accreta associated with index uterine surgery and
indication for index cesarean delivery.

Characteristics of women with no prior uterine surgery
Of the 16 women with placenta accreta who had no known previous uterine surgery
exposure, there were no smokers or women with history of preeclampsia. The average
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gravidity was 2.0 and parity was 0.8. In nine of these women (56%), a potential risk
factor could be identified: three women had a documented abortion, but method was
undocumented; four patients were of advanced maternal age (age ≥ 35 years); one patient
had a history of Hodgkin's lymphoma with radiation therapy; one patient had transfusiondependent thrombotic thrombocytopenic purpura, with weekly or biweekly
plasmapheresis throughout her pregnancy, which ended in fetal demise.
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Discussion
Analysis of pathology-confirmed placenta accreta from a major academic medical center
reveals an increasing rate of non-focal placenta accreta over the past 15 years (OR 1.12,
95% CI 0.98 - 1.29). The increasing rate is consistent with other literature, and with
statistical modeling that predicts an ongoing increase in rate of placenta accreta in
parallel with the trend of the cesarean section rate. This change is driven by an increase
in increta (OR 1.33, 95% CI 0.98 – 1.17) and particularly percreta (OR 1.82 95% CI 1.17
– 2.82). A woman with placenta accreta was 19.9 times more likely to have percreta if
she presented in 2009-2011 compared with a woman in 1996-1999.
With the increased rate of the more invasive degrees of accreta, there is also an increase
in severity of clinical presentation and outcomes. Women with percreta had significantly
more several clinical outcomes as gauged by rate of hysterectomy, ICU admission, blood
transfusion, estimated blood loss and duration of hospital stay compared with women
with placenta accreta. Through the course of this study, there has been an increasing
awareness reflected in the literature of the need to optimize management of placenta
accreta, including through planned early cesarean delivery and use of multi-disciplinary
teams, to minimize morbidity and mortality.(5,10,50) Although this study does not
evaluate management patterns, it is clear that placenta accreta continues to pose a
challenging clinical management scenario. In our case series, there was one maternal
death (1%) among the cases of non-focal placenta accreta in a mutigravida with
antenatally-diagnosed placenta percreta. In our study, women with percreta all had three
or more previous uterine surgery exposures. It is difficult to quantify the degree of
endometrial disruption that occurs by type of uterine surgery; however, in light of the rate
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of rise of the percreta rate, it is worth taking an inclusive view of uterine instrumentation
in evaluating risk of placenta percreta – particularly including myomectomy, endometrial
ablation, and other invasive procedures, as well as curettage.
In this study, there was a significant increase in rate of accreta associated with exposure
to cesarean delivery as the index uterine surgery. This is not surprising, as the cesarean
delivery rate continues to climb. At Yale-New Haven Hospital, the cesarean rate
increased from approximately 20 to over 35% between 1996 and 2009, an increase of
75%.(13) There was a significant change in the rate of primary cesarean exposure for
subjective indications over this time period; however, the rate of placenta accreta with a
prior index cesarean for subjective indications did not increase significantly. However, if
more than 60% of the increase in the primary cesarean delivery rate is due to more
subjective indications suggests, it suggests that, theoretically, with the benefit of
improved tools to guide acute obstetric management, we can safely reduce the cesarean
rate.
Ways to reduce the cesarean rate are under debate. Thorough patient counseling of the
risks and benefits of primary cesarean and also of trial of labor after cesarean –
particularly for women who desire three or more children – is crucial. One author also
suggests setting reimbursement levels for successful VBAC to the same level as that of
elective repeat cesarean deliveries, to prevent any financial incentive for cesarean.(3) A
recent Cochrane review evaluated the effectiveness and safety of non-clinical
interventions for reducing unnecessary cesarean sections.(63) Strategies that show
promise include provider directed efforts, including implementing guidelines with
mandatory second opinion,(64) mandatory second opinion and peer review feedback at
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department meetings(65), guideline implementation with support from local opinion
leaders,(66) and maternal-directed of prenatal education, support programs, computer
patient decision-aids, and intensive group therapy, though evidence for their effectiveness
is less strong to date.(63)
Case identification for cases of placenta accreta was found to be more reliable via
histopathologic diagnosis compared with ICD-9 code query. In our study, ICD-9 code
had a 9% positive predictive value for histopathologic diagnosis of placenta accreta. Of
greatest importance, 69.5% of pathology-confirmed accreta cases were falsely negative
for placenta accreta according to ICD-9 code. Use of ICD-9 code to identify placenta
accreta should be avoided in future investigations. A better strategy would be to use
histopathologic diagnosis, and also to consider establishment of a placenta accreta case
registry to enable broader analysis of this relatively rare pathology.
In addition, there is evidence that the rate of focal placenta accreta has been as high as
5.20 per 1,000 births, but also that sensitivity of diagnosis has varied considerably
between pathologists and degrees of awareness of the problem of milder placenta accreta.
In the case of focal placenta accreta, increase in diagnosis over the middle part of the
study period likely reflected in part an increase in awareness associated with the
publication of several studies highlighting focal accreta. (Personal communication with
Miguel Reyes Mugica MD and Brian West MD, March 7, 2012) Across all types of
accreta, improved diagnostic capabilities through antenatal ultrasound may account for
part of the increase in antenatal diagnosis over the past several decades. However,
standards for histopathologic diagnosis of accreta vera, increta and percreta have not
changed significantly, and it is less likely that the increase in incidence of pathology-
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confirmed accreta is attributable to improved clinician awareness or increased diagnostic
testing.
Placenta accreta is usually considered to be a clinically candid disease, with striking
presentation and outcomes; our true understanding is hindered by a surprising diagnostic
gray area. All agree that a difficult placental delivery and/or massive hemorrhage with
placental or uterine histopathological evidence of basal plate myometrial fibers
constitutes placenta accreta. However, the appropriate characterization of both incidental
pathological diagnosis of accreta without typical clinical signs and clinically severe cases
that are diagnosed by solely clinical findings (e.g. are just diagnosed clinically), remain a
source of relatively unfocused debate. This is particularly concerning, in view of the
evidence that diagnosis of pathology in placenta specimens has considerable interoperator
variability.(55)
Though generally agreed to be increasing, there remains significant variation among
published estimates of the rate of placenta accreta. In addition to differences between
populations, this is due to variation in diagnostic criteria employed – in particular,
clinical versus histopathologic from hysterectomy specimen versus histopathologic from
placental specimen. Both in relation to pathologic diagnosis and in general, a standard
set of criteria for diagnosis of placenta accreta would benefit our efforts to better
understand the patterns of incidence and permit improved comparison between studies.
One of the strengths of this paper was inclusion of all pathology-defined cases identified
in both hysterectomy and placental specimens, unlike most previous studies, which more
often limit pathology specimens to hysterectomy. Although use of stringent inclusion
criteria is important, including only cases in which hysterectomy was performed biases
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our understanding of placenta accreta by failing to consider potentially less clinically
severe, but nevertheless relevant cases of placenta, including cases in which
hysterectomy was a near-miss. In this study, hysterectomy rate averaged 68% across all
non-focal accreta, and exceeded 96% for both placenta increta and percreta. However,
instead of restricting to hysterectomy cases, it is arguably more important to include
criteria that will capture the near-miss cases where conservative management may have
succeeded, in order to gain insight into optimization of management and to have a more
accurate estimate of the extent of this disease. This paper thus may contribute to the
working definition of placenta accreta and the development of standard diagnostic
criteria.
There are a number of limitations to this study. First, by including only pathologyconfirmed cases of placenta accreta, we may have excluded cases that were clinically
significant but in which the placenta was not submitted for pathological examination, or
in which the specimen was insufficient to make a diagnosis, and thus possibly
underestimated the rate of placenta accreta. This possible underestimate is increased by
excluding cases of focal placenta accreta. Nevertheless, comparing the rates with those
found by other recent studies using combined clinical and histopathological diagnosis,
our findings are consistent. Moreover, you would expect broader inclusion criteria to
result in greater sensitivity of diagnosis and thus higher estimated rates.
The small sample size was a limitation of this study. The sample size was further
reduced by our decision to restrict analysis to non-focal accreta; however, the variation in
sensitivity of diagnosis of focal accreta would have introduced unacceptable uncertainty
into our analysis. In the future, extension of a larger project to draw from a broader
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population, including non-tertiary care facilities, would be an improvement. By
stratification of accreta into degree of invasiveness (accreta vera, increta, percreta), it
enabled comparison within our case series, to better define the trends between these
groups. This is particularly relevant, given that our study also found a higher rate of
antenatal diagnosis among cases of placenta percreta compared with increta and
accreta(data not shown), which implies better ability of the clinical team to prepare to
optimize delivery. Despite the small size of our case series, the ability to stratify by type
of accreta and review trends in incidence within these strata is provides an important
insight into patterns of placenta accreta at our institution. Moreover, our demonstration
of the variation in the focal accreta rate based on variation in pathological diagnosis is
relevant for future studies.
A second potential limitation is our baseline assumptions. For instance, by assigning a
standard value for ‘normal’ estimated blood loss (300mL for vaginal birth, 600mL for
cesarean delivery), we may have distorted the actual pattern of blood loss among accreta
deliveries.
Larger studies of placenta accreta are needed. In a future case-control study, it would be
interesting to include analysis of degree of anemia (by hemoglobin/hematocrit), and use
of medications such as nifedipine and other tocolytics, antihypertensives and iron as
exposures to correlate with the outcome of placenta accreta. Each of these might
influence accreta risk by lowering oxygen carrying capacity or blood pressure.
Randomized controlled trials are necessary. However, even before that, establishing use
of accreta tracking systems would be useful to following trends. For instance, at YaleNew Haven Hospital, a research RN in the labor & birth department records all deliveries
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by mode of delivery and indication, and whether delivered by private, university or highrisk provider, which provides a powerful tool for analysis. In a future study, it would
also be useful to seek to compare the rates of antenatal/ultrasound, clinical and
pathological diagnosis in order to help establish the best diagnostic methods for
identifying accreta and related types, in order to prevent misclassification of cases and
better understand etiology and strategies for prevention.
In conclusion, over the last 15 years, the rate of non-focal accreta has increased,
paralleled by an increase in proportion of more severe degrees of invasion and more
severe clinical presentation and outcomes. As antenatal diagnosis and peripartum
management improve, secondary prevention will likely become more effective. Better
provider preparation and provision of multi-disciplinary peripartum care has been shown
to improve outcomes, but will not help turn the tide of this growing problem. It is
important to seek better understanding of potential modifiable risk factors that may aid in
primary prevention, including exposure to uterine surgery, and to balance the short-term
indications that support uterine surgery with the desire to prevent women from
unnecessarily crossing that gateway to increased risk of complications. Central to this
effort will be patient education, including strategic discussion about number of desired
pregnancies and long-term risks. Rates of myomectomy and other uterine procedures
have also increased over time. A clearer picture of the rates of placenta accreta
associated with various uterine surgeries and their contributions to current increases in
placenta accreta is essential, so we can seek to divert childbearing women currently
headed down the potentially risky path of multiple uterine surgeries, and joining the ranks
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of women with greatly increased risk for placenta accreta and the severe outcomes it
forebodes.
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